Novel Strategies and Best Practices for Biosimilar Optimization
This activity will be presented by subject matter experts from two leading academic medical centers in the northeast (Yale and University of Rochester). These two sites have developed infrastructures around this practice to produce the most responsible financial outcomes for their organizations. The purpose of having two sites present on the same topic is so that the audience has the opportunity to learn about two different approaches to the same problem – ultimately leveraging tools / experiences that best fit their needs in their practices.
Target Audience
- Pharmacists
- Pharmacy Technicians
- Other Healthcare Professionals
Learning Objectives
Pharmacists learning objectives:
At the conclusion of this activity, pharmacists should be able to:
- Restate the rationale for developing/implementing a biosimilar management strategy within a health system.
- List variables that contribute to strategy development and selection of biosimilar/reference product.
- Recall workflows and medical record enhancements to facilitate biosimilar management strategy.
- State the importance of partnerships with regional payers to align strategic goals.
Pharmacy technician learning objectives:
At the conclusion of this activity, pharmacy technicians should be able to:
- Recall workflows and medical record enhancements to facilitate biosimilar management strategy.
- State the importance of partnerships with regional payers to align strategic goals.
Additional Information
Attachment | Size |
---|---|
![]() | 134.66 KB |
Faculty
Matthew Groth, PharmD, MS
Director-Pharmaceutical Supply Chain
University of Rochester Medical Center
Bala Athilingam, MBA
Senior Financial Analyst
University of Rochester Medical Center
Holly Kalb, PharmD, MBA
Manager-Revenue Cycle
University of Rochester Medical Center
Taylor Harkness Benoit, PharmD, CSP, BCPS, BCACP
Coordinator, Business Strategy
Yale New Haven Health System
Planning committee
Spencer Martin, PharmD, BCPS, MBA
Network Director
Vizient, Inc.
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Relevant Financial Relationships:
Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
Matthew Groth, PharmD, MS, speaker for this educational activity, is Advisory Board consultant for Par Pharmaceuticals.
All relevant financial relationships listed for these individual(s) have been mitigated.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
![](https://continuingeducation.vizientinc.com/sites/default/files/styles/media_thumbnail/public/media/2022-06/Jointly_Accredited_Provider_JPEG.jpg?itok=lXHaI2tR)
Designation Statement(s):
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.75 ACPE credit hours.
UAN JA0006103-0000-23-283-L04-P
UAN JA0006103-0000-23-283-L04-T
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 1.75 ACPE Pharmacist
- 1.75 ACPE Pharmacy Technician
- 1.75 General CE - Attendance